Evaluation of Pharmacokinetics and Safety of Saroglitazar Magnesium in Participants with Normal Hepatic Function and with Hepatic Impairment, Cholestatic Liver Disease, NASH with Advanced Fibrosis

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 30 Sep 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Saroglitazar (Primary)
Indications Hepatic fibrosis; Liver disorders; Non-alcoholic steatohepatitis; Primary biliary cirrhosis; Primary sclerosing cholangitis
Focus Pharmacokinetics
Sponsors Zydus Discovery DMCC

20 Sep 2024 Status changed from recruiting to completed.
06 Aug 2023 Planned End Date changed from 1 Oct 2023 to 1 Oct 2024.
06 Aug 2023 Planned primary completion date changed from 1 Jun 2023 to 1 Mar 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com